4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-019733
Chief Executive Officer sold 90,000 shares at an average $57.40 ($5,166,298)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2026-01-20 | Sale 10b5-1 | −21,433 | $51.61 | $1,106,157 | 202,768 | D: show line 1 in the form |
| Kulkarni Samarth Chief Executive Officer | 2026-01-20 | Sale 10b5-1 | −8,567 | $52.10 | $446,341 | 194,201 | D: show line 2 in the form |
| Kulkarni Samarth Chief Executive Officer | 2026-01-22 | Sale 10b5-1 | −60,000 | $60.23 | $3,613,800 | 134,201 | D: show line 3 in the form |
| Open-market sales · 90,000 sh · avg $57.40 · $5,166,298 | |||||||
Loading xslF345X05/ownership.xml…